1158083-48-7

Usage

Uses

1. Used in Pharmaceutical Industry:
(1R,2S,5S)-3-[(2S)-2-[[[[1,1-Di(Methyl-d3)ethyl-2,2,2-d3]aMino]carbonyl]aMino]-3,3-di(Methyl-d3)-1-oxobutyl-4,4,4-d3]-6,6-diMethyl-3-azabicyclo[3.1.0]hexane-2-carboxylic Acid Methyl Ester is used as a protected metabolite for the development and study of Hepatitis C virus NS3 serine protease inhibitors, such as Boceprevir. Its application in this field aids in understanding the metabolism and pharmacokinetics of these inhibitors, ultimately contributing to the development of more effective treatments for Hepatitis C.
2. Used in Research and Development:
In the field of research and development, (1R,2S,5S)-3-[(2S)-2-[[[[1,1-Di(Methyl-d3)ethyl-2,2,2-d3]aMino]carbonyl]aMino]-3,3-di(Methyl-d3)-1-oxobutyl-4,4,4-d3]-6,6-diMethyl-3-azabicyclo[3.1.0]hexane-2-carboxylic Acid Methyl Ester serves as a valuable tool for studying the structure-activity relationships of Hepatitis C virus NS3 serine protease inhibitors. By analyzing the interactions between this labelled metabolite and the target enzyme, researchers can gain insights into the design and optimization of more potent and selective inhibitors.
3. Used in Quality Control and Analytical Testing:
(1R,2S,5S)-3-[(2S)-2-[[[[1,1-Di(Methyl-d3)ethyl-2,2,2-d3]aMino]carbonyl]aMino]-3,3-di(Methyl-d3)-1-oxobutyl-4,4,4-d3]-6,6-diMethyl-3-azabicyclo[3.1.0]hexane-2-carboxylic Acid Methyl Ester can be employed as a reference material in quality control and analytical testing processes. Its unique chemical properties and stable isotopic labeling make it suitable for validating the accuracy and precision of analytical methods used in the pharmaceutical industry.
Chemical Properties:
The compound is presented as a white foam, indicating its physical state and appearance. This information can be useful for handling, storage, and characterization purposes in various applications.

Upstream product

• 1158083-47-6 C₁₅H₁₇⁽²⁾H₉N₂O₃*ClH 
• 125214-05-3 tert-[2H₉]butylisocyanate 
• 1092540-45-8 (R)-2-((S)-1-cyano-2,2-d9-dimethylpropylamino)-2-phenylacetamide 
• 1158083-46-5 methyl (1R,2S,5S)-3-((S)-2-((tert-butoxycarbonyl)amino)-4,4,4-trideutero-3,3-bis(trideuteromethyl)butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxylate 
• 1092540-46-9 (S)-2-((R)-2-amino-2-oxo-1-phenylethylamino)-3,3-d9-dimethylbutanamide 
• 1092540-47-0 C₆H₅⁽²⁾H₉N₂O 
• 1092540-48-1 C₆H₄⁽²⁾H₉NO₂*ClH 
• 1158083-37-4 C₁₁H₁₂⁽²⁾H₉NO₄ 
• 90137-14-7 tert-butylaldehyde-d₉ 

Relevant academic research and scientific papers

Design and synthesis of deuterated boceprevir analogs with enhanced pharmacokinetic properties

As part of an ongoing effort to apply the Deuterated Chemical Entity Platform (DCE Platforma) to clinically validated drugs, the synthesis of deuterated analogs of the hepatitis C virus protease inhibitor boceprevir was carried out. The devised synthetic routes allowed for site-selective deuterium incorporation with high levels of isotopic purity. Application of the DCE Platforma to boceprevir enabled the identification of several deuterated analogs that display marked levels of in vitro metabolic stabilization. Most notably, analog 1g exhibits a near doubling of in vitro half-life in human liver microsomal assays. The details of the convergent synthetic route to the boceprevir isotopologs and the results of the metabolic stability assays are described herein.